Medicines play an important part in promoting well-being, preventing ill health and managing disease. Over 700 million prescription items are dispensed in England each year with a cost approaching £8billion.
Medicines management can be defined in several ways:
- The clinical, cost-effective, safe and secure handling of medicines
- A system of processes and behaviours that determines how medicines are used by the NHS and patients
- Enabling people to make the best possible use of medicines
- Our goal is to achieve the best health outcomes for patients where medicines are involved.
If you have any medicines queries please contact NHS Blackpool CCG’s medicines management team on 01253 951306 or email email@example.com
Fylde Coast medicines RAG list
Prescribing position statements
SHARED CARE: Guidelines and information documents
Where shared care has been agreed between prescribers, this section includes documents to support clinicians in clarifying their responsibilities around prescribing and drug/patient monitoring, where relevant.
For drugs listed in the GP+ scheme below, please refer to the GP+ specification (Standard 10: Shared Care). Since drugs may be added to the list in-year, the list below will be the most up-to-date, rather than those listed in the current 2017/18 GP+ document.
Drugs included in GP+ scheme
Drugs not included in GP+ scheme
Patient Group Directions
A Patient Group Direction (PGD) is a written direction that allows the supply and/or administration of a specified medicine(s), by named authorised health professionals, to a well-defined group of patients requiring treatment for a specific condition. The patient must always fit the defined criteria and organisations must ensure that healthcare professionals supplying and/or administering medicines under a PGD are fully trained, competent individuals who are authorised to do so.
Organisations must be in possession of PGDs that are appropriately signed and fully authorised, unsigned copies are not the legal document and are for information purposes only.
Cumbria and Lancashire CCGs have a collaborative arrangement to produce the PGDs for the national vaccination programme.
Vaccine and immunisation PGDs: The signed copies of these PGDs have been distributed to organisations and GP practices. Each organisation or practice is required to keep the signed copy and ensure all health professionals who will be working under it are authorised and have signed the second page under the managerial content section. The documents at the following link are for information only and are not the legal document: www.lancsmmg.nhs.uk/pgds
Patient information leaflets
Primary Care Rebate Schemes
Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.
Current Primary Care Rebate Schemes in place:
- Clenil Modulite (Beclometasone) – commenced July 2019
- ConvaTec – commenced January 2020
- Dabigatran (Pradaxa) – commenced November 2020
- Degarelix (Firmagon) – commenced September 2016
- Edoxaban – commenced September 2018
- Fostair NEXThaler – commenced May 2021
- Fostair pMDI – commenced July 2021
- Fencino (Fentanyl) – commenced October 2018
- Lantus – commenced April 2020
- Longtec – commenced July 2019
- Prostap (Leuprorelin) – commenced April 2020
- Rivaroxaban (Xarelto) – commenced July 2019
- Sereflo – commenced July 2019
- Toujeo (Insulin Glargine) – commenced July 2021
- Zacco (Clobazam) – commenced March 2021
- Zoladex (Goserelin) commenced July 2019